Awakn Life Sciences Initiates Phase 3 Trial for AWKN-001 in Severe Alcohol Use Disorder
Awakn Life Sciences Corp. (NEO: AWKN, OTCQB: AWKNF)
August 9, 2024: Toronto, Canada
Awakn Life Sciences Corp., a leading biotech company focused on the development of ketamine-based therapies for mental health and addiction, has announced the screening of the first patient in its Phase 3 clinical trial evaluating AWKN-001, its investigational treatment for severe alcohol use disorder (AUD).
This Phase 3 trial is a randomized, double-blind, placebo-controlled study designed to assess the safety and efficacy of a single treatment cycle of AWKN-001 in reducing alcohol consumption and improving alcohol-related outcomes in individuals with AUD. The trial will enroll approximately 200 participants at sites in the United States, United Kingdom, and Australia.
- AWKN-001 is a ketamine-assisted therapy that has shown promising results in earlier clinical trials for AUD.
- Ketamine has been shown to have rapid-acting antidepressant and anti-addiction effects.
- The Phase 3 trial will provide further evidence on the safety and efficacy of AWKN-001 as a potential treatment for AUD.
The initiation of this Phase 3 trial is a significant milestone for Awakn and represents a key step in the development of AWKN-001. If successful, this trial could lead to the approval of AWKN-001 as a new treatment option for individuals with AUD.
About Awakn Life Sciences
Awakn Life Sciences Corp. is a clinical-stage biotechnology company focused on the development of ketamine-based therapies for mental health and addiction. The company's lead drug candidate, AWKN-001, is a ketamine-assisted therapy for AUD.
About Alcohol Use Disorder
AUD is a chronic relapsing brain disease that is characterized by excessive alcohol use, despite negative consequences. AUD is a major public health problem, affecting millions of people worldwide. Current treatment options for AUD are limited and often ineffective.
For more information, visit www.awaknlifesciences.com.
Disclaimer: This news release contains forward-looking statements that involve risks and uncertainties. Actual events or results could differ materially from those projected in this forward-looking information.
Https Ca Linkedin Com Company Awakn Life Sciences
Https Clival Com News Awakn Life Sciences Begins Patient Screening In More Kare Phase 3 Trial
Comments